
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Almac expands technical, project, and operational resources in Asia.
Almac
reported the expansion of its clinical services and technologies capabilities to include technical, project, and operational resources in Asia. The company has established regional hubs in Singapore and Japan to improve the need to conduct clinical trials in Asia and manage global trials from the region.
As part of the expansion, Almac is building a new secondary packaging facility in Singapore, which is expected to open by the end of 2014.
Source:
Almac






